CD38 and Miyoshi myopathy: Specifically, bortezomib, carfilzomib, and ixazomib (proteasome inhibitors [PIs]), lenalidomide and pomalidomide (immunomodulatory agents [IMiDs]), and daratumumab (anti‐CD38 antibody) have revolutionized the MM treatment landscape [1, 2, 3, 4, 5, 6, 7, 8, 9].